268 related articles for article (PubMed ID: 25075878)
1. The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona.
Murta-Nascimento C; Romero AI; Sala M; Lorente JA; Bellmunt J; Rodero NJ; Lloreta J; Hospital À; Burón A; Castells X; Macià F
Eur J Cancer Prev; 2015 Jul; 24(4):335-9. PubMed ID: 25075878
[TBL] [Abstract][Full Text] [Related]
2. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
[TBL] [Abstract][Full Text] [Related]
3. Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy.
Pantarotto J; Malone S; Dahrouge S; Gallant V; Eapen L
BJU Int; 2007 Mar; 99(3):564-9. PubMed ID: 17166241
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
Sakai N; Taguri M; Kobayashi K; Noguchi S; Ikeda S; Koh H; Satomi Y; Furuhata A
Int J Urol; 2015 Aug; 22(8):747-52. PubMed ID: 26011393
[TBL] [Abstract][Full Text] [Related]
5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
6. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
7. Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity.
Steinberger E; Kollmeier M; McBride S; Novak C; Pei X; Zelefsky MJ
BJU Int; 2015 Oct; 116(4):596-603. PubMed ID: 25345838
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
9. Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: Results from a population-based analysis of 10,794 cases.
Sharp L; McDevitt J; Brown C; Carsin AE; Comber H
Cancer; 2017 Jul; 123(13):2543-2550. PubMed ID: 28297071
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
11. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
12. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract][Full Text] [Related]
13. Effect of smoking on survival from non-small cell lung cancer: a retrospective Veterans' Affairs Central Cancer Registry (VACCR) cohort analysis.
Bhatt VR; Batra R; Silberstein PT; Loberiza FR; Ganti AK
Med Oncol; 2015 Jan; 32(1):339. PubMed ID: 25429831
[TBL] [Abstract][Full Text] [Related]
14. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
16. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
17. A worse prognosis for smokers with prostate cancer.
Daniell HW
J Urol; 1995 Jul; 154(1):153-7. PubMed ID: 7776411
[TBL] [Abstract][Full Text] [Related]
18. Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy.
Tollefson MK; Boorjian SA; Gettman MT; Rangel LJ; Bergstralh EJ; Karnes RJ
Urol Oncol; 2013 Nov; 31(8):1483-8. PubMed ID: 22578510
[TBL] [Abstract][Full Text] [Related]
19. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
